SCI Pharmtech Inc
TWSE:4119
SCI Pharmtech Inc
Revenue
SCI Pharmtech Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
SCI Pharmtech Inc
TWSE:4119
|
Revenue
NT$1.4B
|
CAGR 3-Years
5%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
0%
|
|
|
Y
|
YungShin Global Holding Corp
TWSE:3705
|
Revenue
NT$7.8B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
3%
|
|
|
Formosa Laboratories Inc
TWSE:4746
|
Revenue
NT$4.6B
|
CAGR 3-Years
14%
|
CAGR 5-Years
11%
|
CAGR 10-Years
5%
|
|
|
ScinoPharm Taiwan Ltd
TWSE:1789
|
Revenue
NT$3.5B
|
CAGR 3-Years
6%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-3%
|
|
|
Lotus Pharmaceutical Co Ltd
TWSE:1795
|
Revenue
NT$17.6B
|
CAGR 3-Years
11%
|
CAGR 5-Years
17%
|
CAGR 10-Years
23%
|
|
|
Standard Chem & Pharm Co Ltd
TWSE:1720
|
Revenue
NT$6.7B
|
CAGR 3-Years
14%
|
CAGR 5-Years
11%
|
CAGR 10-Years
8%
|
|
SCI Pharmtech Inc
Glance View
SCI Pharmtech Corp. is engaged in the biotechnology and medical care industry. The company is headquartered in Taoyuan, Taoyuan. The company went IPO on 2002-08-12. The firm's main products include APIs, API intermediates and special and precision chemicals. The firm distributes its products in domestic market and to overseas markets, including Europe, the Americas, the rest areas of Asia and others
See Also
What is SCI Pharmtech Inc's Revenue?
Revenue
1.4B
TWD
Based on the financial report for Sep 30, 2024, SCI Pharmtech Inc's Revenue amounts to 1.4B TWD.
What is SCI Pharmtech Inc's Revenue growth rate?
Revenue CAGR 10Y
0%
Over the last year, the Revenue growth was 24%. The average annual Revenue growth rates for SCI Pharmtech Inc have been 5% over the past three years , -9% over the past five years .
You don't have any saved screeners yet